Cargando…

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes

Detalles Bibliográficos
Autores principales:	Zeidner, Joshua F., Mazerolle, Flora, Norton, Jonathan, Regnault, Antoine, Kristo, Fjoralba, Romero, Heather, Fram, Robert J., Faller, Douglas V., Dalal, Mehul, Ades, Lionel, Sekeres, Mikkael A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071104/ https://www.ncbi.nlm.nih.gov/pubmed/36475522 http://dx.doi.org/10.3324/haematol.2022.281856

Ejemplares similares

Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30
por: Regnault, Antoine, et al.
Publicado: (2021)

Economic Impact of Transformation to Acute Myeloid Leukemia Among Actively Managed Patients with Higher-Risk Myelodysplastic Syndromes in the United States
por: Kota, Vamsi, et al.
Publicado: (2022)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes
por: Mukherjee, Sudipto, et al.
Publicado: (2023)

Reliance on metrics is a fundamental challenge for AI
por: Thomas, Rachel L., et al.
Publicado: (2022)

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
por: Zeidan, Amer M., et al.
Publicado: (2022)

Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes
por: Gabrilove, Janice, et al.
Publicado: (2008)

Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy
por: Fenaux, Pierre, et al.
Publicado: (2017)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

P732: ANALYSIS OF PATIENT-REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTS
por: Sekeres, Mikkael, et al.
Publicado: (2023)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
por: Snow, Anson, et al.
Publicado: (2022)

Molecular features of early onset adult myelodysplastic syndrome
por: Hirsch, Cassandra M., et al.
Publicado: (2017)

Under COVID of the night
por: Sekeres, Mikkael A.
Publicado: (2020)

Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax
por: Jehangir, Waqas, et al.
Publicado: (2020)

Interpretability and reliance on simulation
por: Nachman, Ben
Publicado: (2020)

Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes:An analysis of four SWOG studies
por: Othus, Megan, et al.
Publicado: (2018)

Self-reliance : a strategy for development /
Publicado: (1980)

PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023)

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
por: Sekeres, Mikkael A., et al.
Publicado: (2018)

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States
por: Bell, Jill A., et al.
Publicado: (2018)

Glutamine reliance in cell metabolism
por: Yoo, Hee Chan, et al.
Publicado: (2020)

S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
por: Platzbecker, Uwe, et al.
Publicado: (2023)

PB2184: IMPACT OF TRANSFUSION BURDEN ON HEALTH-RELATED QUALITY OF LIFE AND FUNCTIONING IN PATIENTS WITH MYELOFIBROSIS: POST HOC ANALYSIS OF SIMPLIFY-1 AND -2
por: Mesa, Ruben, et al.
Publicado: (2023)

S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
por: Santini, Valeria, et al.
Publicado: (2023)

Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes
por: Koutsavlis, Ioannis
Publicado: (2016)

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
por: Duong, Hien K, et al.
Publicado: (2009)

Pumping blood with self-reliance and cooperation
por: Iruela-Arispe, M. Luisa
Publicado: (2018)

Glycolytic reliance promotes anabolism in photoreceptors
por: Chinchore, Yashodhan, et al.
Publicado: (2017)

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2022)

A Mixed Methods Study to Explore Relevant Metrics for a Results Framework Measuring the Public Health Impact of Reliance-Based Pathways
por: Adams, Inez, et al.
Publicado: (2023)

Magnetic Resonance Myocardial Feature Tracking in Transfusion-Dependent Myelodysplastic Syndrome
por: Alonso-Fernandez-Gatta, Marta, et al.
Publicado: (2021)

A geno-clinical decision model for the diagnosis of myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2021)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia
por: Giagounidis, Aristoteles, et al.
Publicado: (2014)

Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
por: Komrokji, Rami S., et al.
Publicado: (2020)

Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence
por: Nazha, Aziz, et al.
Publicado: (2019)

A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
por: Bell, Jill A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8suddejg8onjtls9nf3cbrnt5q